Diagnosis and classification of neuromyelitis optica (Devic's Syndrome)

Autoimmunity Reviews

Volumn 13, Issue 4-5, 2014, Pages 531-533

  Drori, Tali ^a   Chapman, Joab ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Autoimmune CNS diseases; Autoimmunity; Diagnostic criteria; Neuromyelitis optica; NMO IgG antibodies

Indexed keywords

IMMUNOGLOBULIN G;

CLINICAL FEATURE; DISEASE CLASSIFICATION; HUMAN; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC NEURITIS; REVIEW;

AUTOIMMUNE CNS DISEASES; AUTOIMMUNITY; DIAGNOSTIC CRITERIA; NEUROMYELITIS OPTICA; NMO-IGG ANTIBODIES;

ANIMALS; AQUAPORIN 4; AUTOANTIBODIES; HUMANS; IMMUNOGLOBULIN G; NEUROMYELITIS OPTICA; RECURRENCE;

EID: 84896318406     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.01.034     Document Type: Review

References (19)

1. Allbutt T.C. On the ophthalmoscopic signs of spinal disease. Lancet 1870, 1:76-78.
2. Devic E. Myelite subaigue compliquee de neurite opticqoe. Bull Med 1894, 8:1033-1034.
3. Wingerchuk D.M., Hogancamp W.F., Hogancamp W.F., Obrien P.C., Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1118.
4. Lennon V.A., Kryzer T.J., Pittock S.J., Verkma A.S., Hinson S.R. IgG marker of optic spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473-477.
5. Matiello M., Kim H.J., Kim W., et al. Familial neuromyelitis optica. Neurology 2010, 75:310-315.
6. Uzawa A., Mori M., Kuwabara S. Neuromyelitis optica: concept, immunology and treatment. J clinical neurosci 2013, 10.1016/j.jocn.2012.12.022.
7. Misu T., Fujihara K., Nakashima L., Sato S., Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005, 65:1479-1482.
8. Poppe A.Y., Lapierre Y., Melancon D., et al. Neuromyelitis optica with hypothalamic involvement. Multiple sclerosis 2005, 76:617-621.
9. Maganda S.M., Matiello M., Pittock S.J., et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009, 72:712-717.
10. Lennon V.A., Wingerchuk D.M., Kryzer T.J., et al. A serum autoantibody marker of neuromyelitis optica: distinction form multiple sclerosis. Lancet 2004, 364:2106-2112.
11. Verkman A.S. Aquaporins in clinical medicine. Annu Rev Med 2012, 63:303-316.
12. Papadopoulos M., Verkman A.S. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012, 11:535-544.
13. Retelade J., Verkman A.S. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol 2012, 44:1519-1530.
14. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
15. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:805-815.
16. Matiello M., Lennon V.S., Jacob A., et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008, 70:2197-2200.
17. Weinshenker B.G., Wingerchuk D.M., Vukusic S., et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566-569.
18. Jacob A., Mckeon A., Nakashima I., et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013, 84:922-930.
19. Akmar-Demir G., Tuzun E., Waters P., et al. Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol 2011, 258:464-470.